Keywords
ofloxacin
ornidazole
spectroscopy
simultaneous estimation
How to Cite
Abstract
The aim of this work was to develop and validate simple, accurate and precise spectroscopic methods (multicomponent, dual wavelength and simultaneous equations) for the simultaneous estimation and dissolution testing of ofloxacin and ornidazole tablet dosage forms. The medium of dissolution used was 900 ml of 0.01N HCl, using a paddle apparatus at a stirring rate of 50 rpm. The drug release was evaluated by developed and validated spectroscopic methods. Ofloxacin and ornidazole showed 293.4 and 319.6nm as λ max in 0.01N HCl. The methods were validated to meet requirements for a global regulatory filing. The validation included linearity, precision and accuracy. In addition, recovery studies and dissolution studies of three different tablets were compared and the results obtained show no significant difference among products.
References
S. S.Incilay, T.Ayla, Anal. Lett., 36 (2003) 1163–1181.
M. D.Bethesda, Directors of the American Society of Hospital Pharmacists.
Drug information USA, 88 (1988) 415–420.
Proceedings of the World Health Organisation Meeting on Use of Quinolones in Food
Animals and Potential Impact on Human Health, Geneva, Switzerland, (1998).
A. Kucers, S. M. Crowe, M. L.Graysan, J. F. Hoy, The Use of Antibiotics, 55th Edn., 1997.
P. S. Francis, J. L. Adcock, Analytica Chimica Acta, 54 (2005) 3–12.
P. Gao, J. Shi, J. N. Li, S. M. Liu, Chin. J. Appl. Chem., 22 (2005) 578–580.
C. L. Tong, G. H. Xiang, D. J. Huang, W. P. Liu, Chin. J. Anal. Chem., 32 (2004) 619–621.
R. G. Finch, Drugs, 49 (1995) 144–151.
N. M. Lopez, A. M. Palermob, M. D. Mudryc, M. A. Carballo, Toxicol. In Vitro., 17 (2003) 35–40.
H. M. Sílvia, P. Lutiane, Z. A. Marcela, B. Liziane, G. C. Simone, Sci. Pharm., 76 (2008) 541–554.
J. Emami, J. Pharm. Sci., 9 (2006) 169–189.
M. D. Rockville, FDA Guidance for Industry, 1997.
British pharmacopoeia, Licensing division HMSO, Norwich, (2003) 357.
United State Pharmacopoeia, United State Pharmacopoeial Convention, (2007) 1355.
European Pharmacopoeia, EDQM, Council of Europe, Strasbourg, 5th edn., (2005) 2131.
V. M. Shinde, B. S. Desai, N. M. Tendolkar, Indian Drugs, 35 (1998) 715.
A. P. Argekar, U. S. Kapadia, S. V. Raj, S. S. Kunjur, Indian Drugs, 33 (1996) 261.
Y. S. Krishnaiah, M. Y. Indira, P. Bhaskar, Journal of Drug Targeting, 11 (2003)109.
P. U. Patel, B. N. Subaghia, M. M. Patel, Indian Drugs, 93 (2004) 28.
M. Bakshi, B. Singh, A. Singh, S. Singh, J. Pharm. Biomed. Anal., 26 (2001) 891.
A. Behl, M. Ahuja, A. S. Dhake, Indian J. Pharm. Sci., 67 (2005) 479.
N. S. Kamble, B. Venkatachalam, Indian Drugs, 42 (2005) 723.
M. Gandhimathi, T. K. Ravi, S. Nilima, Indian J. Pharm. Sci., 68 (2006) 838-840.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2018 Eclética Química Journal